Literature DB >> 465280

Pharmacokinetics of hydrochlorothiazide in patients with congestive heart failure.

B Beermann, M Groschinsky-Grind.   

Abstract

1. Hydrochlorothiazide (HCT, 50-75 mg) was administered orally to seven patients with cardiac failure. 2. Plasma levels and urinary concentration of HCT were determined by GLC. 3. The gastrointestinal uptake of the diuretic in three patients was reduced to approximately half that seen in healthy controls. 4. Plasma halflife of HCT was correlated with endogenous creatinine clearance. 5. Pharmacokinetics of HCT are considerably changed in cardiac failure.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 465280      PMCID: PMC1429681          DOI: 10.1111/j.1365-2125.1979.tb04646.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  The clinical pharmacology of hydrochlorothiazide.

Authors:  R V FORD
Journal:  South Med J       Date:  1959-01       Impact factor: 0.954

2.  Some observations on the pharmacology of hydrochlorothiazide.

Authors:  J H MOYER; M FUCHS; S IRIE; T BODI
Journal:  Am J Cardiol       Date:  1959-01       Impact factor: 2.778

3.  A student exercise in clinical pharmacology: Renal effects of diuretics.

Authors:  J P Gilmore; W M O'Brien; E D Brand; M J Peach; T C Westfall
Journal:  Curr Ther Res Clin Exp       Date:  1970-11

4.  Pharmacokinetics of hydrochlorothiazide in man.

Authors:  B Beermann; M Groschinsky-Grind
Journal:  Eur J Clin Pharmacol       Date:  1977-12-02       Impact factor: 2.953

5.  Absorption, metabolism, and excretion of hydrochlorothiazide.

Authors:  B Beermann; M Groschinsky-Grind; A Rosén
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

6.  Antihypertensive effect of various doses of hydrochlorothiazide and its relation to the plasma level of the drug.

Authors:  B Beermann; M Groschinsky-grind
Journal:  Eur J Clin Pharmacol       Date:  1978-05-31       Impact factor: 2.953

  6 in total
  15 in total

Review 1.  New insights into carbonic anhydrase inhibition, vasodilation, and treatment of hypertensive-related diseases.

Authors:  Erik R Swenson
Journal:  Curr Hypertens Rep       Date:  2014-09       Impact factor: 5.369

Review 2.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics in heart failure. An updated review.

Authors:  F V Shammas; K Dickstein
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

Review 4.  Antihypertensive therapy in the aged patient. Clinical pharmacokinetic considerations.

Authors:  R W Piepho; K J Fendler
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

Review 5.  Diuretics. Clinical pharmacology and therapeutic use (Part I).

Authors:  A Lant
Journal:  Drugs       Date:  1985-01       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics of diuretics.

Authors:  B Beermann; M Groschinsky-Grind
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

Review 7.  The elderly patient. A special case for diuretic therapy.

Authors:  D E Hyams
Journal:  Drugs       Date:  1986       Impact factor: 9.546

8.  Pharmacokinetics of hydrochlorothiazide in relation to renal function.

Authors:  C Niemeyer; G Hasenfuss; U Wais; H Knauf; M Schäfer-Korting; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Bioavailability of quinidine in congestive heart failure.

Authors:  C T Ueda; B S Dzindzio
Journal:  Br J Clin Pharmacol       Date:  1981-06       Impact factor: 4.335

Review 10.  Telmisartan/hydrochlorothiazide: in the treatment of essential hypertension.

Authors:  Caroline Fenton; Gillian M Keating; Lesley J Scott
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.